News

Under the terms of the agreement, MDRNA will receive upfront cash and double-digit profit sharing on commercial sales of calcitonin. In addition, Par will assume MDRNA’s supply and

Hyperion Therapeutics has reported positive top-line results from its Phase II study of HPN-100 for the treatment of urea cycle disorders. The Phase II study was an open-label,

Mr Williams’s career with Sanofi Pasteur began when he joined the division as a finance manager in 1978. Mr Williams held a series of increasingly senior positions, culminating

Through this new subsidiary, Genomma Lab will sell new product lines within the categories of analgesics, cold remedies, anti-fungal, anti-inflammatory, expectorants and multivitamins, among others. Genomma Lab said

Ligand Pharmaceuticals, a biotechnology company, has identified a new lead for advancement in its alliance with GlaxoSmithKline. The newly identified lead compound is from a program being evaluated

Under the terms of the agreement, Mitsubishi Tanabe Pharma has obtained exclusive rights to develop and commercialize EnVivo’s alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan,

Archemix, a biotechnology company, has initiated a Phase IIa clinical trial of its anti-von Willebrand Factor aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy

With this agreement, Eisai obtained the exclusive rights for development and marketing of Urief in 10 ASEAN (Association of South East Asian Nations) countries, as well as India

The agreement provides Sophysa with the rights to sell in Belgium and Luxembourg, and includes minimum purchase requirements. According to Misonix, the SonaStar is used by neuro and